FDA's latest warning letters in the dietary supplement sector are examples of firms failing to document corrective actions to achieve good manufacturing practices compliance and expecting contract manufacturers to shoulder their GMP burden.
A May 12 letter to Central Point, Ore., firm VitaPurity Corp. and a May 16 letter to Morhaim Pharmalab Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?